| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39c68430bcb778feae2ad4e9640ad0ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-6054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 |
| filingDate |
2007-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0a185de0fce2cd4e9d0e3d903f2a197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5073ee35383c85dcba1381809ee2b7e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d17810b07d40642724f070bb62043f2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f53bd4fbfe84988f23bbd737103a05d |
| publicationDate |
2011-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8008469-B2 |
| titleOfInvention |
Antisense compound for inducing immunological tolerance |
| abstract |
A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11642364-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11020417-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11225662-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11236329-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009082547-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010184670-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10905782-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015048395-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8741863-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9499583-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9161948-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10300149-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10888578-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9572899-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9862946-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10487326-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10144762-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8592386-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11732259-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8877725-B2 |
| priorityDate |
2003-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |